{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dobis DR"],"funding":["NCRR NIH HHS","NIEHS NIH HHS"],"pagination":["458-64"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2951876"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["43(4)"],"pubmed_abstract":["Occupational exposure to beryllium (Be) results in Be sensitization (BeS) that can progress to pulmonary granulomatous inflammation associated with chronic Be disease (CBD). Be-specific lymphocytes are present in the blood of patients with BeS and in the blood and lungs of patients with CBD. Sulfasalazine and its active metabolite, mesalamine, are clinically used to ameliorate chronic inflammation associated with inflammatory bowel disease. We tested whether sulfasalazine or mesalamine could decrease Be-stimulated peripheral blood mononuclear cell (PBMC) proliferation in subjects with CBD and BeS and Be-induced cytokine production in CBD bronchoalveolar lavage (BAL) cells. CBD (n = 25), BeS (n = 12) and healthy normal control (n = 6) subjects were enrolled and ex vivo proliferation and cyt"],"journal":["American journal of respiratory cell and molecular biology"],"pubmed_title":["Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production."],"pmcid":["PMC2951876"],"funding_grant_id":["1 UL1 RR025780","R01 ES-012504","R01 ES-017582","P01 ES11810"],"pubmed_authors":["Sawyer RT","Gillespie MM","Newman LS","Maier LA","Dobis DR","Day BJ"],"additional_accession":[]},"is_claimable":false,"name":"Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production.","description":"Occupational exposure to beryllium (Be) results in Be sensitization (BeS) that can progress to pulmonary granulomatous inflammation associated with chronic Be disease (CBD). Be-specific lymphocytes are present in the blood of patients with BeS and in the blood and lungs of patients with CBD. Sulfasalazine and its active metabolite, mesalamine, are clinically used to ameliorate chronic inflammation associated with inflammatory bowel disease. We tested whether sulfasalazine or mesalamine could decrease Be-stimulated peripheral blood mononuclear cell (PBMC) proliferation in subjects with CBD and BeS and Be-induced cytokine production in CBD bronchoalveolar lavage (BAL) cells. CBD (n = 25), BeS (n = 12) and healthy normal control (n = 6) subjects were enrolled and ex vivo proliferation and cyt","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Oct","modification":"2025-04-05T12:24:18.858Z","creation":"2019-03-27T00:34:43Z"},"accession":"S-EPMC2951876","cross_references":{"pubmed":["19901345"],"doi":["10.1165/rcmb.2009-0150OC","10.1165/rcmb.2009-0150oc"]}}